aTyr Pharma is a biotechnology business based in the US. aTyr Pharma shares (LIFE) are listed on the NASDAQ and all prices are listed in US Dollars. aTyr Pharma employs 56 staff and has a trailing 12-month revenue of around $588,000.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $1.65 - $2.09 |
|---|---|
| 50-day moving average | $1.76 |
| 200-day moving average | $1.59 |
| Wall St. target price | $24.60 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.88 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
| Revenue TTM | $588,000 |
|---|---|
| Gross profit TTM | $-32,422,000 |
| Return on assets TTM | -29.37% |
| Return on equity TTM | -55.61% |
| Profit margin | 0% |
| Book value | $1.24 |
| Market Capitalization | $131.1 million |
TTM: trailing 12 months
We're not expecting aTyr Pharma to pay a dividend over the next 12 months.
aTyr Pharma's shares were split on a 1:14 basis on 30 June 2019 . So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your aTyr Pharma shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for aTyr Pharma shares which in turn could have impacted aTyr Pharma's share price.
Over the last 12 months, aTyr Pharma's shares have ranged in value from as little as $1.65 up to $2.09. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while aTyr Pharma's is 1.188. This would suggest that aTyr Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
aTyr Pharma, Inc. , a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co. , Ltd. for the development and commercialization of efzofitimod for ILDs in Japan.
We dug through 60 years of Berkshire Hathaway annual shareholder letters to bring you 9 lessons from Warren Buffett: “The Oracle of Omaha.”
These are the stocks to buy when you don’t have much to spend.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Compare pros, cons, research tools and reviews for these two trading platforms.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Compare pros, cons, research tools and reviews for these two trading platforms.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.